Bausch Health to acquire liver drug developer Durect for $1.75 per share
Source: SeekingAlpha
2025-07-29 08:35:55 ET
More on Bausch Health Companies, DURECT
- Bausch Health: Repricing Potential Driven By Deleveraging
- Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript
- Bausch Health Companies Inc. 2025 Q1 - Results - Earnings Call Presentation
- Bausch Health to redeem ~$602M of outstanding notes due 2026
- Insider trades: Broadcom, Dell among notable names this week
Read the full article on Seeking Alpha
For further details see:
Bausch Health to acquire liver drug developer Durect for $1.75 per share
Bausch Health Companies Inc.
NASDAQ: BHC:CC
BHC:CC Trading
-0.34% G/L:
$5.88 Last:
1,784,767 Volume:
$5.90 Open:
BHC:CC Latest News
February 23, 2026 08:00:00 am
Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada
February 19, 2026 08:00:00 am
Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres
